GlassScriptPhysician profile
Aziz N Ander
NPI 1316131832
$1,788.04
in general payments reported to CMS, 2019-2025
29 companies · $70.07 in 2025
The $70.07 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $481 · 2021: $213 · 2022: $90.74 · 2023: $60.61 · 2024: $58.52 · 2025: $70.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.80 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $371.61 | 2019-2020 | |
| Abbvie INC. | $238.09 | 2021-2024 | Botox |
| Allergan, INC. | $186.33 | 2019-2022 | |
| Amgen INC. | $145.21 | 2019-2020 | |
| Sk Life Science, INC. | $75.01 | 2020 | |
| Novartis Pharmaceuticals Corporation | $65.35 | 2019-2025 | |
| Tersera Therapeutics LLC | $63.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.22 | 2019 | |
| Eisai INC. | $45.52 | 2019 | |
| Ucb, INC. | $42.90 | 2025 | Briviact |
| Incyte Corporation | $37.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $36.62 | 2019 | |
| Daiichi Sankyo INC. | $36.50 | 2019 | |
| Lilly USA, LLC | $32.78 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $32.65 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.44 | 2019 | |
| Seagen INC. | $28.57 | 2020 | |
| Amag Pharmaceuticals, INC. | $24.30 | 2019 | |
| Puma Biotechnology, INC. | $24.10 | 2021 | |
| Biogen, INC. | $23.83 | 2021 | |
| Coherus Oncology, INC. | $22.90 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.11 | 2019 | |
| Karyopharm Therapeutics INC. | $20.21 | 2022 | |
| Celgene Corporation | $18.90 | 2019 | |
| Dendreon Pharmaceuticals LLC | $17.29 | 2019 | |
| Kyowa Kirin, INC. | $15.62 | 2019 | |
| Neurelis, INC. | $13.40 | 2024 | Valtoco |
| Clovis Oncology, INC. | $8.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aziz Ander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.